Skip to content

Diaphragmatic ultrasound evaluation of the antagonistic effect of sugammadex on rocuronium after liver surgery in patients with different preoperative liver function grades: a clinical study

Diaphragmatic ultrasound evaluation of the antagonistic effect of sugammadex on rocuronium after liver surgery in patients with different preoperative liver function grades: a clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040013
Enrollment
Unknown
Registered
2020-11-18
Start date
2021-01-03
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Application of muscle relaxant antagonists

Interventions

Child Class A patient group:Diaphragm ultrasound was used to evaluate the residual muscle relaxation of sugammadex antagonizes rocuronium after surgery.
Child Class B patient group:Diaphragm ultrasound was used to evaluate the residual muscle relaxation of sugammadex antagonizes rocuronium after surgery.
Child Class C patient group:Diaphragm ultrasound was used to evaluate the residual muscle relaxation of sugammadex antagonizes rocuronium after surgery.

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic radical liver cancer surgery under general anesthesia; 2. Postoperative application of sugammadex to antagonize the residual effect of rocuronium muscle relaxation; 3. Aged 18 to 65 years old male or female; 4. ASA rating: Level I - Level III; 5. 18kg/m2 <= BMI <= 27.9 kg/m2; 6. Voluntary signing of informed consent; 7. Non-lactating women, women of childbearing age must have a negative pregnancy test.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to rocuronium and sugammadex; 2. Patients with central and peripheral nervous system diseases, such as polio, Parkinson's disease, peripheral neuropathy, etc.; 3. Patients with neuromuscular diseases: multiple sclerosis, myasthenia gravis, atrophic myotonia, etc.; 4. Diaphragm dysfunction, pneumothorax, pleural effusion, mediastinal gas; 5. Pregnant or breastfeeding women; 6. The investigator judged that the patient was not eligible for the other conditions of the clinical trial.

Design outcomes

Primary

MeasureTime frame
Postoperative residual incidence of muscle relaxation;Baseline recovery rate of diaphragm;

Secondary

MeasureTime frame
Muscle relaxation recovery time;PACU monitoring time;Postoperative extubation time;Intraoperative rocuronium dosage;Adverse reactions and pulmonary complications 7 days after surgery;

Countries

China

Contacts

Public ContactYun Lin

Union Hospital, Tongji Medical College, Huazhong University of Science & Technology

frank0130@126.com+86 13986268403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026